HCR.20.013 – PERIMET – A multi-dimensional research program to improve treatment of peritoneal metastatic disease

Route: Health care research, sickness prevention and treatment

Cluster question: 085 Every tumour is different, so how can we come to understand cancer well enough to develop a treatment for each and every type?

Peritoneal metastatic disease (PMD) is common to a large number of solid malignancies, including ovarian (OC), colorectal (CRC), and gastric cancer (GC). It is associated with high morbidity and a dismal prognosis. PMD is characterized by a distinct tumor biology that sets it apart from localized malignancies, and cancers that spread through the blood and lymphatic system to distant organs. Because it is a molecularly distinct disease entity, currently employed therapies against PMD have limited efficacy.
The pan-cancer nature of PMD, its poorly characterized biology, and the specific treatment strategies currently employed, call for a multi-dimensional approach to improve outcomes. The lack of molecular innovation in this area, and insufficiently met medical need will allow PERIMET to force a real breakthrough in PMD in the next 5 years. Specifically, we propose a comprehensive program where the following aims will be addressed:

– Fundamentally understand PMD – PMD has received limited research attention. PERIMET joins expert scientists to investigate the molecular mechanisms and characteristics that drive PMD in CRC, OC, and GC. For this, state-of-the-art disease models including organoids, PDX models, as well as primary patient samples are used. For the first time, PMD is studied as one disease entity regardless of organ of origin.
– Find better treatment – we will identify and target specific vulnerabilities that result from the tumor biology that enables PMD, perform high-throughput drug screens on PMD and follow-up promising leads in preclinical efficacy studies.
– Translate into clinical practice – we will leverage the unique clinical expertise on PMD in the Netherlands to perform clinical studies in patients using the most promising and feasible leads identified within this initiative. By working together with drug companies and legal bodies, patients will immediately benefit from PERIMET results. Also, due to the severity of the disease, quality-of-life and palliative care is an important focus.

Keywords

drug development, health economics, nursing science, Peritoneal metastases, quality of life

Other organisations

Oncode Institute

Submitter

Organisation Amsterdam UMC, AMC
Name Prof. Dr. L. (Louis) Vermeulen
E-mail l.vermeulen@amsterdamumc.nl
Website www.vermeulenlab.org